Utilization of oncoprotein-pulsed dendritic cells as tumor vaccines

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 8, 2001, Pages 463-466

  Bubeník, Jan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; B CELL LYMPHOMA; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SARCOMA; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, CD; CANCER VACCINES; DENDRITIC CELLS; ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 0034922569     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320000220     Document Type: Review

References (38)

1. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
2. Dendritic cells and the control of immunity
3. Induction of a CD8 cytotoxic T lymphocyte response by cross priming requires cognate CD4 help
4. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
5. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
6. Induction of tumor immunity and cytotoxic T lymphocytes responses using dendritic cells transfected with messenger RNA amplified from tumor cells
7. Gene transfer for immunotherapy of cancer
8. Dendritic cell-based cancer vaccines
9. Local cytokine therapy of cancer: Interleukin-2, interferons and related cytokines
10. Activation of human dendritic cells through CD40 cross-linking
11. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
12. + T cell immunity
13. DNA-based immunization by in vivo transfection of dendritic cells
14. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis
15. A fail-safe mechanism for maintaining self-tolerance
16. Dendritic cells: Unique leukocyte populations which control the primary immune response
17. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
18. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
19. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function
20. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
21. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro
22. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
23. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo
24. Feeding dendritic cells with tumour antigens: Self-service buffet or a la carte?
25. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene
26. Retroviral transduction of human dendritic cells with a tumour-associated antigen gene
27. Transfected human dendritic cells to induce antitumor immunity
28. Immunization with virus-modified tumor cells
29. Intra-pinna anti-tumour vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine
30. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
31. Dendritic cells as adjuvants for immune-mediated resistance to tumors
32. CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L
33. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
34. Immunotherapy using dendritic cells
35. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor - But not monocyte-derived dendritic cells
36. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
37. CD40 ligand-dependent T cell activation, requirement of B7-CD28 signaling through CD40
38. + T-cell responses and are more effective than DNA vaccines at generating antitumor immunity